Abstract
Mycludex B (MYR) is a new promising anti-HDV therapy, but the effectiveness and safety of long-term administration in compensated cirrhotics treated in a real-life setting are presently unknown. Aim of this study was therefore to describe the effectiveness, safety and impact on HDV/HBV-specific T cell profiles in the first two European patients treated with MYR outside clinical trials. Methods. A 69-year-old female and 51-year-old male Caucasian HBeAg-negative patients with HDV related compensated cirrhosis on long-term term TDF treatment, started MYR 10 mg/day on January and May 2018 in a compassionate use program. Liver function tests, bile acids and virological markers were monitored every 4 weeks. HDV RNA was tested by RoboGene®.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
